Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1822]

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2...

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer...

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan yields promising results in HER2-positive breast cancer patients pretreated with TDM-1 ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML...

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

KRd consolidation in MM patients with a positive PET-CT after standard first...

Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway

KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial ( Dr Fredrik Schjesvold - Oslo University Hospital, Oslo, Norway )

Complete remission after induction chemotherapy determines clinical efficacy of...

Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden

Complete remission after induction chemotherapy determines clinical efficacy of relapse-preventive immunotherapy in AML ( Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden )

FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible...

Prof David Cairns - University of Leeds, Leeds, UK

FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM ( Prof David Cairns - University of Leeds, Leeds, UK )

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-negative ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

Dasatinib vs imatinib for paediatric Ph ALL

Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA

Dasatinib vs imatinib for paediatric Ph ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )

Study of quadruple combination for induction resistant myeloma reveals novel...

Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Study of quadruple combination for induction resistant myeloma reveals novel immune checkpoints ( Dr Yael Cohen - Tel Aviv Sourasky Medical Center, Tel Aviv, Israel )

KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM

Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria

KRd vs KTd followed by carfilzomib maintenance in newly diagnosed MM ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )

Azacitidine plus nivolumab in older adults with AML or MDS

Prof Annette Hay - Queen's University, Ontario, Canada

Azacitidine plus nivolumab in older adults with AML or MDS ( Prof Annette Hay - Queen's University, Ontario, Canada )

More from ecancer